416 related articles for article (PubMed ID: 27183388)
1. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.
Tian G; Courtney AN; Jena B; Heczey A; Liu D; Marinova E; Guo L; Xu X; Torikai H; Mo Q; Dotti G; Cooper LJ; Metelitsa LS
J Clin Invest; 2016 Jun; 126(6):2341-55. PubMed ID: 27183388
[TBL] [Abstract][Full Text] [Related]
2. IL-21 Selectively Protects CD62L
Ngai H; Tian G; Courtney AN; Ravari SB; Guo L; Liu B; Jin J; Shen ET; Di Pierro EJ; Metelitsa LS
J Immunol; 2018 Oct; 201(7):2141-2153. PubMed ID: 30111631
[TBL] [Abstract][Full Text] [Related]
3. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
4. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
[TBL] [Abstract][Full Text] [Related]
5. LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells.
Ngai H; Barragan GA; Tian G; Balzeau JC; Zhang C; Courtney AN; Guo L; Xu X; Wood MS; Drabek JM; Demberg T; Sands CM; Chauvin-Fleurence CN; Di Pierro EJ; Rosen JM; Metelitsa LS
Cancer Immunol Res; 2023 Feb; 11(2):171-183. PubMed ID: 36484736
[TBL] [Abstract][Full Text] [Related]
6. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A; Xu X; Courtney AN; Tian G; Barragan GA; Guo L; Amador CM; Ghatwai N; Rathi P; Wood MS; Li Y; Zhang C; Demberg T; Di Pierro EJ; Sher AC; Zhang H; Mehta B; Thakkar SG; Grilley B; Wang T; Weiss BD; Montalbano A; Subramaniam M; Xu C; Sachar C; Wells DK; Dotti G; Metelitsa LS
Nat Med; 2023 Jun; 29(6):1379-1388. PubMed ID: 37188782
[TBL] [Abstract][Full Text] [Related]
7. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
Song L; Asgharzadeh S; Salo J; Engell K; Wu HW; Sposto R; Ara T; Silverman AM; DeClerck YA; Seeger RC; Metelitsa LS
J Clin Invest; 2009 Jun; 119(6):1524-36. PubMed ID: 19411762
[TBL] [Abstract][Full Text] [Related]
8. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
[TBL] [Abstract][Full Text] [Related]
10. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
Landoni E; Woodcock MG; Barragan G; Casirati G; Cinella V; Stucchi S; Flick LM; Withers TA; Hudson H; Casorati G; Dellabona P; Genovese P; Savoldo B; Metelitsa LS; Dotti G
Nat Commun; 2024 Jan; 15(1):89. PubMed ID: 38167707
[TBL] [Abstract][Full Text] [Related]
11. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
12. A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor.
Landoni E; Smith CC; Fucá G; Chen Y; Sun C; Vincent BG; Metelitsa LS; Dotti G; Savoldo B
Cancer Immunol Res; 2020 Jan; 8(1):57-69. PubMed ID: 31719055
[TBL] [Abstract][Full Text] [Related]
13. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
14. A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.
Yang S; Archer GE; Flores CE; Mitchell DA; Sampson JH
Cancer Immunol Immunother; 2013 Nov; 62(11):1649-62. PubMed ID: 23982483
[TBL] [Abstract][Full Text] [Related]
15. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
17. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
[TBL] [Abstract][Full Text] [Related]
18. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
19. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
20. Murine DX5
Werner JM; Damian M; Farkas SA; Schlitt HJ; Geissler EK; Hornung M
J Immunol Res; 2018; 2018():8175810. PubMed ID: 30364054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]